115 related articles for article (PubMed ID: 38506561)
1. Other-cause mortality in incidental prostate cancer.
Di Bello F; Baudo A; de Angelis M; Jannello LMI; Siech C; Tian Z; Goyal JA; Collà Ruvolo C; Califano G; La Rocca R; Morra S; Acquati P; Saad F; Shariat SF; Carmignani L; de Cobelli O; Briganti A; Chun FKH; Longo N; Karakiewicz PI
Prostate; 2024 Jun; 84(8):731-737. PubMed ID: 38506561
[TBL] [Abstract][Full Text] [Related]
2. Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.
Wenzel M; Würnschimmel C; Chierigo F; Tian Z; Shariat SF; Terrone C; Saad F; Tilki D; Graefen M; Mandel P; Kluth LA; Chun FKH; Karakiewicz PI
Prostate; 2021 Aug; 81(11):728-735. PubMed ID: 34010465
[TBL] [Abstract][Full Text] [Related]
3. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer.
Dell'Oglio P; Karnes RJ; Joniau S; Spahn M; Gontero P; Tosco L; Fossati N; Kneitz B; Chlosta P; Graefen M; Marchioro G; Bianchi M; Sanchez-Salas R; Karakiewicz PI; Poppel HV; Montorsi F; Briganti A;
Urol Oncol; 2016 May; 34(5):234.e13-9. PubMed ID: 26706120
[TBL] [Abstract][Full Text] [Related]
4. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities.
Würnschimmel C; Wenzel M; Collà Ruvolo C; Nocera L; Tian Z; Saad F; Briganti A; Shariat SF; Mandel P; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
World J Urol; 2021 Oct; 39(10):3781-3787. PubMed ID: 33978812
[TBL] [Abstract][Full Text] [Related]
5. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract][Full Text] [Related]
6. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer.
Bandini M; Marchioni M; Preisser F; Zaffuto E; Tian Z; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
World J Urol; 2018 Sep; 36(9):1399-1407. PubMed ID: 29717358
[TBL] [Abstract][Full Text] [Related]
7. How socioeconomic and clinical factors impact prostate-cancer-specific and other-cause mortality in prostate cancer stratified by clinical stage: Competing-risk analysis.
He H; Han D; Xu F; Lyu J
Prostate; 2022 Mar; 82(4):415-424. PubMed ID: 34927741
[TBL] [Abstract][Full Text] [Related]
8. Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality.
Mazzone E; Preisser F; Nazzani S; Tian Z; Bandini M; Gandaglia G; Fossati N; Soulières D; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2018 Oct; 16(5):376-384.e1. PubMed ID: 29954690
[TBL] [Abstract][Full Text] [Related]
9. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
[TBL] [Abstract][Full Text] [Related]
10. Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer.
Chierigo F; Borghesi M; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Hoeh B; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Montorsi F; Chun FKH; Shariat SF; Mantica G; Suardi N; Terrone C; Karakiewicz PI
Prostate; 2022 May; 82(6):740-750. PubMed ID: 35226380
[TBL] [Abstract][Full Text] [Related]
11. Survival outcomes of locally advanced prostate cancer in patients aged < 50 years after local therapy in the contemporary US population.
Sheng W; Zhang H; Lu Y
Int Urol Nephrol; 2018 Aug; 50(8):1435-1444. PubMed ID: 29982959
[TBL] [Abstract][Full Text] [Related]
12. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients.
Moltzahn F; Karnes J; Gontero P; Kneitz B; Tombal B; Bader P; Briganti A; Montorsi F; Van Poppel H; Joniau S; Spahn M
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):31-7. PubMed ID: 25535100
[TBL] [Abstract][Full Text] [Related]
13. A non-cancer-related survival benefit is associated with partial nephrectomy.
Sun M; Trinh QD; Bianchi M; Hansen J; Hanna N; Abdollah F; Shariat SF; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI
Eur Urol; 2012 Apr; 61(4):725-31. PubMed ID: 22172373
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients.
Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Mazzone E; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Eur Urol Oncol; 2018 Aug; 1(3):215-222. PubMed ID: 31102624
[TBL] [Abstract][Full Text] [Related]
15. Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer.
Dell'Oglio P; Bishr M; Boehm K; Trudeau V; Larcher A; Tian Z; Sosa J; Moschini M; Saad F; Capitanio U; Briganti A; Graefen M; Montorsi F; Karakiewicz PI
Eur Urol Focus; 2018 Dec; 4(6):834-841. PubMed ID: 28753853
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years.
Marchioni M; Preisser F; Bandini M; Nazzani S; Tian Z; Kapoor A; Cindolo L; Abdollah F; Tilki D; Briganti A; Montorsi F; Shariat SF; Schips L; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):467-473. PubMed ID: 29398456
[TBL] [Abstract][Full Text] [Related]
17. Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns.
Würnschimmel C; Wenzel M; Chierigo F; Flammia RS; Mori K; Tian Z; Shariat SF; Saad F; Briganti A; Suardi N; Terrone C; Gallucci M; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
Prostate; 2021 Aug; 81(11):778-784. PubMed ID: 34057220
[TBL] [Abstract][Full Text] [Related]
18. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma.
Bianchi M; Gandaglia G; Trinh QD; Hansen J; Becker A; Abdollah F; Tian Z; Lughezzani G; Roghmann F; Briganti A; Montorsi F; Karakiewicz PI; Sun M
Urol Oncol; 2014 Jan; 32(1):46.e1-7. PubMed ID: 24054864
[TBL] [Abstract][Full Text] [Related]
19. Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification.
Abdollah F; Boorjian S; Cozzarini C; Suardi N; Sun M; Fiorino C; di Muzio N; Karakiewicz PI; Montorsi F; Karnes RJ; Briganti A
Eur Urol; 2013 Oct; 64(4):557-64. PubMed ID: 23506833
[TBL] [Abstract][Full Text] [Related]
20. Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy.
Mistretta FA; Mazzone E; Palumbo C; Knipper S; Tian Z; Nazzani S; Lattouf JB; Musi G; Perrotte P; Montanari E; Shariat SF; Montorsi F; Saad F; de Cobelli O; Karakiewicz PI
Clin Genitourin Cancer; 2019 Aug; 17(4):e793-e801. PubMed ID: 31182339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
